CDK4 and breast cancer: Earlier, we showed camizestrant has antitumor activity in twice as many ER+ breast cancer PDX models as fulvestrant, including those derived from tumors that are primary or metastatic, naïve or exposed to ET and/or CDK4/6i, and with different ESR1m status (Figs. 2–4).